WYTEC INTERNATIONAL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that WYTEC INTERNATIONAL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $394.1K | Apr 6, 2022 |
| FY2021 | Dec 31, 2020 | $1.08M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $405.5K | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | $305.7K | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | $48.6K | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $69.9K | Apr 2, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $131.1K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $255.6K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $413.9K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $394.1K | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $1.08M | Apr 6, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $75.5K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $84.7K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $74.1K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $24.8K | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $285.2K | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $186.4K | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | $104.4K | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | $48.1K | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $45.2K | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($3.67M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($3.31M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($2.08M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($3.64M) | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | ($2.02M) | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($2.85M) | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | ($3.12M) | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | ($3.67M) | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | ($3.10M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($3.09M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($3.09M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.91M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($3.71M) | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | ($2.11M) | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($2.71M) | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | ($2.99M) | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | ($3.49M) | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | ($3.09M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $379.9K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $131.8K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $41.0K | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $21.2K | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $4.5K | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | $23.7K | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | $10.9K | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $6.1K | Apr 2, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.76M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $3.00M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.93M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.63M | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $2.30M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $2.75M | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.89M | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | $3.32M | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $2.93M | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.70M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($1.86M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.34M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($1.74M) | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | ($1.66M) | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($2.62M) | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | ($3.00M) | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | ($2.85M) | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | ($2.98M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.9K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $848 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $953 | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $13.0K | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $25.0K | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | $68.1K | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $323.6K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $1.22M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $272.0K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $452.4K | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $951.2K | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $1.19M | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.09M | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | $4.09M | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $3.73M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.61M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $2.10M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.25M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $2.33M | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $1.95M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $1.43M | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.55M | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | $2.14M | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $2.10M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($2.28M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($876.1K) | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | ($2.98M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($1.88M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | ($1.00M) | Aug 10, 2023 |
| FY2021 | Dec 31, 2019 | ($234.6K) | Apr 6, 2022 |
| FY2020 | Dec 31, 2018 | $543.0K | Jun 25, 2021 |
| FY2019 | Dec 31, 2017 | $1.95M | Jun 29, 2020 |
| FY2017 | Dec 31, 2016 | $1.62M | Apr 2, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($34.78M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($31.11M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($27.80M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($25.72M) | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | ($22.07M) | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($20.12M) | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | ($17.26M) | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | ($14.14M) | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | ($10.47M) | Apr 2, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.35M | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | $1.10M | Mar 29, 2024 |
| FY2022 | Dec 31, 2022 | $2.00M | Aug 10, 2023 |
| FY2021 | Dec 31, 2021 | $968.2K | Apr 6, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 6, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Aug 10, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 16.75M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 13.29M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 12.20M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 6.95M | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | 6.09M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | 5.43M | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | 4.97M | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | 3.86M | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | 1.06M | Apr 2, 2018 |